Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time.
about
Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genomeHepatitis B virus and its sexually transmitted infection - an update.Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta-analysis.Development and evaluation of a baseline-event-anticipation score for hepatitis deltaPrognostic values of fluctuations in serum levels of alanine transaminase in inactive carrier state of HBV infection.Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese.Natural history of chronic hepatitis B: phases in a complex relationship.Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.Early termination of immune tolerance state of hepatitis B virus infection explains liver damage.A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B.Large variations in risk of hepatocellular carcinoma and mortality in treatment naïve hepatitis B patients: systematic review with meta-analysesPeritumoral small ephrinA5 isoform level predicts the postoperative survival in hepatocellular carcinomaCharacteristics of chronic hepatitis B patients who underwent liver biopsies.Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients.Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALTDiscontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice.Dilemma of HBsAg seroconversion in chronic hepatitis B infection: Dilemma of HBsAg in chronic HBVHigh level of intercellular adhesion molecule-1 affects prognosis of patients with hepatocellular carcinoma.Cell death and cell death responses in liver disease: mechanisms and clinical relevanceBasal core promoter mutation is associated with progression to cirrhosis rather than hepatocellular carcinoma in chronic hepatitis B virus infection.Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Histological grading and staging of liver and its relation to viral loads in chronic anti-HBe positive hepatitis.Evaluation of the need for treatment on 72 subjects with anti-HBe positive chronic hepatitis B.Relationship Between Hepatic Steatosis and the Elevation of Aminotransferases in HBV-Infected Patients With HBe-Antigen Negativity and a Low Viral Load.Long noncoding RNA CPS1-IT1 suppresses the metastasis of hepatocellular carcinoma by regulating HIF-1α activity and inhibiting epithelial-mesenchymal transition.Effects of sex and generation on hepatitis B viral load in families with hepatocellular carcinoma.Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment.What can we learn from hepatitis B virus clinical cohorts?Hepatitis B: 50 years after the discovery of Australia antigen.OncomiR miR-96 and miR-182 promote cell proliferation and invasion through targeting ephrinA5 in hepatocellular carcinoma.Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.Long-term outcome of inactive and active, low viraemic HBeAg-negative-hepatitis B virus infection: Benign course towards HBsAg clearance.Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis.The prognosis of hepatitis B inactive carriers in Japan: a multicenter prospective study.Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion.Clinical course of chronic hepatitis B (CHB) presented with normal ALT in Asian American patients.Serum microRNA-29 levels correlate with disease progression in patients with chronic hepatitis B virus infection.Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand Māori: results from a 28-year follow-up study.
P2860
Q28080587-29C70627-1185-451C-881B-E70A699450EAQ30235028-0B63685D-4D59-41B2-81D7-3A5836FFD685Q30251618-E3369A7A-3D66-4811-B7D5-346FA645818AQ33414249-FCDE463E-5056-4738-96DE-FD7A64FA147BQ33580037-81C82257-D26E-4C23-850A-D21F568FECF8Q33718958-7A3D2A50-25A6-46C3-9461-0CD1AB946ED9Q33773772-368F281A-BD01-4C3B-BB44-C1D72E9B0375Q34036650-024CAF78-7117-4266-95E9-34E543E4C075Q34168465-89FA303E-C37D-4B2B-BD18-C4BCB559C00FQ34179245-69A7F61D-AF2B-4231-A48F-47AC3A4624BBQ34184642-869B0B26-D97A-4EBD-BB14-62743339AD97Q34203972-BB07F703-9BD9-4D95-9D61-F6D6CD7F38C3Q34364217-BF280842-8397-4920-B491-824D29DAF69AQ34414362-556BEE82-4104-493B-B982-5203615F5E1AQ34462246-3E97B4EC-8964-4064-B975-7149F461C9C8Q35036631-504F8337-8621-4C34-89ED-A6372A182886Q35060142-78538E6C-A47C-4474-989D-2F90E7DCF010Q35507407-3462A9CC-A915-4EEA-A492-AC051588CBABQ35767923-BA214438-F3F1-4D1F-930F-82CD0E85D49FQ35938040-571E5E51-E5E3-4E56-862D-BCDAA2B034F9Q36451722-AE753918-D842-457A-9278-5E5FB6747CABQ36973383-D24E83E3-45D0-4E6A-82C2-4261D98EEEF0Q37128478-5795784A-E5F5-4B89-BEAE-69BE5CA6FB09Q37128552-44077477-234F-44F0-B206-FCD3092FAD0DQ37206503-BCEC1111-0487-4A0C-8C34-5B6E70254C45Q37536645-81DD944A-1947-4408-9A52-11BAAFF4E349Q37629719-256557B8-443E-42C5-B0F7-7A07FC125C11Q37696844-19417525-F883-4D1E-A775-2BB3B3E5B965Q38295846-220B6F61-08F5-4B62-B921-F1A871382D9BQ38568256-FA00541E-9EBC-44E9-8CC0-00BC009901FAQ38911638-A904A6E2-7D14-42CD-8B77-8250869D7EF3Q39649139-67907C7E-E625-4983-B413-68836B3BF4AFQ39737072-F5B6C5DF-9831-49B8-ACA8-B69D38A3B285Q40291383-921D2DAD-D29C-4A03-8F63-F8FD4126D70BQ40468451-34E52035-9C78-4411-B1B5-703BF49C2A5DQ40699496-9053AF4A-9203-4035-93AC-F19BB01EEA25Q40707285-9B34FE34-D318-42F1-97E9-105BED6F3CE7Q42174357-21EE2B1D-6523-49A6-8233-AD7173916806Q42199097-70B2DB49-3445-4561-A3AF-69F6CAB46A56Q42206945-D94E76E5-5DF5-40B5-BE31-89C41024D6D5
P2860
Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Long-term outcome of hepatitis ...... otransferase levels over time.
@en
Long-term outcome of hepatitis ...... otransferase levels over time.
@nl
type
label
Long-term outcome of hepatitis ...... otransferase levels over time.
@en
Long-term outcome of hepatitis ...... otransferase levels over time.
@nl
prefLabel
Long-term outcome of hepatitis ...... otransferase levels over time.
@en
Long-term outcome of hepatitis ...... otransferase levels over time.
@nl
P2093
P2860
P356
P1433
P1476
Long-term outcome of hepatitis ...... otransferase levels over time.
@en
P2093
Chia-Ming Chu
Dar-In Tai
Deng-Yn Lin
I-Shyan Sheen
Shi-Ming Lin
P2860
P304
P356
10.1002/HEP.22878
P407
P50
P577
2009-06-01T00:00:00Z